Valuation: Paion AG

Market Cap 144K 162K 134K 122K 230K 15.56M 232K 1.62M 631K 7.94M 606K 593K 25.52M P/E 2021
-3.89x
P/E 2022 -53x
Enterprise Value 9.87M 11.06M 9.19M 8.37M 15.75M 1.07B 15.87M 111M 43.22M 544M 41.52M 40.63M 1.75B EV / Sales 2021
14.1x
EV / Sales 2022 1.22x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
1 day-85.71%
1 week-85.71%
Current month-85.71%
1 month-85.71%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.01
0.01
Current year 0.01
Extreme 0.01
0.07
1 year 0.01
Extreme 0.01
0.07
3 years 0
Extreme 0.0001
0.38
5 years 0
Extreme 0.0001
20.8
10 years 0
Extreme 0.0001
36
Manager TitleAgeSince
Chief Executive Officer 62 2023-08-31
Director of Finance/CFO - 2022-05-31
Director TitleAgeSince
Director/Board Member 65 2012-09-30
Director/Board Member 75 2017-05-31
Director/Board Member - 2019-05-21
Change 5-day change 1-year change 3-year change Capi.($)
-85.71%-85.71% - - 369K
+4.16%+3.42%+49.37%+94.17% 74.16B
-0.37%-3.88%+19.75%+78.35% 57.39B
+1.63%+0.98%+3.83%+38.21% 47.64B
+0.50%+2.94%+344.62%+722.17% 44.29B
+3.05%-1.80%+28.78%+34.51% 42.5B
+1.00%-1.46%+5.17%+111.90% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.76%-1.45%-7.44%-11.12% 24.34B
Average -7.40%-0.59%+53.86%+127.69% 43.39B
Weighted average by Cap. +1.55%-0.84%+58.06%+136.94%

Financials

2021 2022
Net sales 7.13M 7.99M 6.64M 6.04M 11.38M 770M 11.47M 80.25M 31.22M 393M 30M 29.35M 1.26B 33.25M 37.27M 30.98M 28.19M 53.08M 3.59B 53.48M 374M 146M 1.83B 140M 137M 5.89B
Net income -21.79M -24.42M -20.3M -18.47M -34.78M -2.35B -35.04M -245M -95.42M -1.2B -91.67M -89.7M -3.86B -579K -649K -539K -491K -924K -62.51M -931K -6.52M -2.54M -31.9M -2.44M -2.38M -103M
Net Debt 13.77M 15.43M 12.83M 11.67M 21.98M 1.49B 22.15M 155M 60.31M 759M 57.94M 56.69M 2.44B 9.72M 10.9M 9.06M 8.24M 15.52M 1.05B 15.64M 109M 42.58M 536M 40.91M 40.03M 1.72B
Logo Paion AG
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Employees
64
Date Price Change Volume